Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
BUSINESS
Fujifilm-Sponsored Avigan Trial to Complete Enrollment on Aug. 16
Fujifilm Toyama Chemical plans to complete the patient enrollment on August 16 for its stalled PIII clinical trial in Japan for its antiviral agent Avigan (favipiravir) for the treatment of COVID-19, a company official said. The Fujifilm group company believes…
To read the full story
Related Article
- Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020
- Avigan’s COVID-19 Use Up for PAFSC Review on December 21
December 17, 2020
- Avigan to Come Up for PAFSC Review This Month
December 16, 2020
- (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
- Fujifilm’s Avigan COVID-19 Data Won’t Be Fully Ready until 1 Month from Now
August 21, 2020
- Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.
July 13, 2020
- Fujifilm Inks Global Avigan Deal with Dr. Reddy’s, Global Response Aid
July 2, 2020
- Fujifilm’s Avigan COVID-19 Trial Might Continue into July
June 9, 2020
- Most Mild COVID-19 Patients Recovered on Avigan, but Careful Interpretations Needed for Single-Arm Study: Interim Report
May 27, 2020
- Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
BUSINESS
- FRONTEO, Daiichi Sankyo Expand AI Collaboration into Toxicity Data Analysis
August 20, 2025
- PPIs Prescribed to 6.38 Million in July, Two APIs Control 60%: Intage
August 20, 2025
- FDA Pushes Back Decision on Hunter Syndrome Gene Therapy
August 20, 2025
- Santen Secures Asia Rights to RemeGen’s VEGF/FGF Eye Drug RC28-E
August 20, 2025
- Foreign Pharma Sales in Japan Projected to Rise 1.8% in 2025: Fuji Keizai
August 20, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…